A prospective randomized phase III trial by Reynolds et al (2009) [11] failed to demonstrate substantial difference in survival according to RRM1 levels in lung cancer patients treated with gemcitabine and carboplatin or gemcitabine monotherapy. This evidence concerns the gene RRM1 and lung cancer.